Impact of Endocrine Therapy Regimens for Early-Stage ER+/HER2-Breast Cancer on Contralateral Breast Cancer Risk

Scientists adapted an established Cancer Intervention and Surveillance Network model to simulate life histories of multiple US female birth-cohorts diagnosed with stage 0-III ER+/HER2- breast cancer receiving different durations of two endocrine therapy regimens.